In a move that will amplify its already-strong ties with the pharmaceutical industry, Sanford-Burnham Medical Research Institute in San Diego just received a $100 million donation to hasten the academic development of new therapeutics.
This is reflective of an overall increase in translational medicine – in these changing times, the biopharma industry has a growing reliance on academia, a new Battelle report says.
The donation comes from philanthropist Conrad Prebys, a San Diego real estate tycoon.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“We should be doing all we can to shorten suffering and to extend people’s lives,” UT-San Diego reports. “Sanford-Burnham is the engine that is driving this ‘bench-to-bedside’ work. It’s going to pay dividends for a long, long time.”
This isn’t the first such gift to Sanford-Burnham: In January 2014, an anonymous donor gave the research institute an impressive $275 million for translational medicine.
Coupled with that announcement, Sanford-Burnham said it would up its partnerships with the pharmaceutical industry to move drug development forward. At the time, it hired away Perry Nisen, a senior VP at GlaxoSmithKline, to serve as Sanford-Burnham’s CEO.